Last Wednesday, when Boston Scientific Corp. (BSC) pushed out the expected close of its $27 billion takeout of Guidant Corp. by as much as a week, Mergers & Acquisitions Report got solid checks BSC was on track to get its antitrust nod.
To read the entire story, you must be logged in.
Please log in now or register with us.
